Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 06 Sep 2022
COVID-19: a global opinion on bivalent vaccines in mid-September
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
Posted by Michael Wonder on 10 Jul 2022
Monkeypox: a preventive vaccination offered to those most at risk of exposure
8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...
Posted by Michael Wonder on 02 May 2022
HAS clarifies the framework for use of Xevudy
29 April 2022 - After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 21 Apr 2022
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...
Posted by Michael Wonder on 30 Mar 2022
Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination
29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...
Posted by Michael Wonder on 19 Mar 2022
COVID-19: a second booster reserved for those most at risk
18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 09 Aug 2021
Competition from biosimilars drives price reductions for biologics in the French single payer health system
6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...
Posted by Michael Wonder on 24 Mar 2021
The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study
22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...
Posted by Michael Wonder on 15 Dec 2020
Vaccination strategy against SARS-Cov-2
15 December 2020 - Intermediate recommendations on the methods of implementing vaccination. ...
Posted by Michael Wonder on 04 Dec 2020
COVID-19 vaccine will be free of charge, 1 million inoculations set for January, French PM say
3 December 2020 - After the vaccination of an initial 1 million people in January an additional 14 million at ...
Posted by Michael Wonder on 17 Sep 2020
Transparency Commission publishes its opinion on Veklury
17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...
Posted by Michael Wonder on 17 Jan 2020
France removes state funding for dementia drugs
17 January 2020 - The first country in Europe to act on concerns over limited effectiveness. ...